Prodia Acquires 30% Stake in Biotech Firm ProSTEM to Advance Personalized Healthcare
Main Takeaways
|
JAKARTA, Investortrust.id — PT Prodia Widyahusada Tbk (PRDA), one of Indonesia’s leading clinical laboratory networks, has acquired a 30% stake in biotechnology company PT Prodia StemCell Indonesia (ProSTEM) to expand its presence in regenerative medicine and personalized healthcare services.
The deal, involving the purchase of 69,512 shares from PT Prodia Utama, marks a strategic shift for Prodia toward biotechnology innovation. ProSTEM is recognized as a pioneer in stem cell research and development in Indonesia, having recorded a 46% revenue growth in 2024.
President Director of Prodia Dewi Muliaty said the acquisition is part of the company’s long-term strategy to offer more personalized and impactful diagnostic and treatment solutions. “This investment reaffirms Prodia’s commitment to building a sustainable healthcare ecosystem,” she said in an official statement on Tuesday, July 1, 2025.
She added that ProSTEM’s focus on advanced cell-based therapies aligns with Prodia’s vision to deliver cutting-edge medical solutions that are both scientifically sound and socially relevant.
Prodia Finance Director Liana Kuswandi noted that ProSTEM’s solid financial performance was a key driver behind the acquisition. “Their 46% revenue growth is clear evidence of an effective and competitive business strategy,” she said.
The acquisition is expected to enhance service synergies between the two entities, strengthening Prodia’s research and development (R&D) capabilities and its innovation pipeline for personalized treatment approaches. This includes targeted therapies for degenerative, autoimmune, and chronic diseases.
Andi Widjaja, Founder and President Commissioner of both Prodia and ProSTEM, emphasized that the collaboration symbolizes a strong synergy between two major players in Indonesia’s healthcare sector. He also highlighted that the move supports President Prabowo Subianto’s QuickWin program in the health sector, particularly in improving the nation’s life expectancy.